AXNX Axonics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AXNX

Price (delayed)

$68.49

Market cap

$3.49B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.31

Enterprise value

$3.28B

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers ...

Highlights
AXNX's gross profit is up by 34% year-on-year and by 6% since the previous quarter
The revenue has increased by 31% year-on-year and by 6% since the previous quarter
The net income has plunged by 162% from the previous quarter but it has soared by 66% YoY
AXNX's EPS has dropped by 158% since the previous quarter but it has soared by 68% year-on-year
The company's debt rose by 14% QoQ
Sector: Healthcare
Industry: Medical Devices
Website: http://www.axonicsmodulation.com
Peers: OM OBIO

Key stats

What are the main financial stats of AXNX
Market
Shares outstanding
51.02M
Market cap
$3.49B
Enterprise value
$3.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.57
Price to sales (P/S)
9.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.47
Earnings
Revenue
$387.14M
EBIT
-$13.95M
EBITDA
-$1.1M
Free cash flow
-$16.29M
Per share
EPS
-$0.31
Free cash flow per share
-$0.32
Book value per share
$12.3
Revenue per share
$7.6
TBVPS
$10.58
Balance sheet
Total assets
$715.56M
Total liabilities
$88.46M
Debt
$31.61M
Equity
$627.1M
Working capital
$433.64M
Liquidity
Debt to equity
0.05
Current ratio
9.96
Quick ratio
8.25
Net debt/EBITDA
197.51
Margins
EBITDA margin
-0.3%
Gross margin
75.2%
Net margin
-4.1%
Operating margin
-8%
Efficiency
Return on assets
-2.3%
Return on equity
-2.6%
Return on invested capital
-4.4%
Return on capital employed
-2.1%
Return on sales
-3.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AXNX stock price

How has the Axonics stock price performed over time
Intraday
0.44%
1 week
1.14%
1 month
1.68%
1 year
26.13%
YTD
10.06%
QTD
1.87%

Financial performance

How have Axonics's revenue and profit performed over time
Revenue
$387.14M
Gross profit
$291.31M
Operating income
-$30.87M
Net income
-$15.95M
Gross margin
75.2%
Net margin
-4.1%
The net income has plunged by 162% from the previous quarter but it has soared by 66% YoY
The company's net margin has shrunk by 141% QoQ but it has surged by 74% YoY
The operating margin has surged by 57% year-on-year but it has declined by 13% since the previous quarter
The company's operating income rose by 45% YoY but it fell by 18% QoQ

Growth

What is Axonics's growth rate over time

Valuation

What is Axonics stock price valuation
P/E
N/A
P/B
5.57
P/S
9.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.47
AXNX's EPS has dropped by 158% since the previous quarter but it has soared by 68% year-on-year
The P/B is 13% above the last 4 quarters average of 4.9 but 2.6% below the 5-year quarterly average of 5.7
AXNX's equity is up by 9% year-on-year
The price to sales (P/S) is 64% lower than the 5-year quarterly average of 25.2 but 8% higher than the last 4 quarters average of 8.3
The revenue has increased by 31% year-on-year and by 6% since the previous quarter

Efficiency

How efficient is Axonics business performance
The ROE has plunged by 160% from the previous quarter but it has soared by 70% YoY
AXNX's ROA has plunged by 156% from the previous quarter but it has soared by 69% YoY
AXNX's ROIC has soared by 85% YoY but it is down by 38% QoQ
AXNX's ROS has soared by 77% year-on-year but it is down by 38% since the previous quarter

Dividends

What is AXNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AXNX.

Financial health

How did Axonics financials performed over time
Axonics's current ratio has increased by 40% YoY but it has decreased by 7% from the previous quarter
AXNX's quick ratio is up by 38% year-on-year but it is down by 9% since the previous quarter
The company's debt is 95% lower than its equity
AXNX's debt to equity has soared by 150% year-on-year and by 25% since the previous quarter
The company's debt rose by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.